Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Joins the Hunt for a Coronavirus Treatment

By Prosper Junior Bakiny - Mar 13, 2020 at 11:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Via a new partnership, the pharmaceutical giant is putting its muscle behind the efforts of therapeutic antibody specialist AbCellera Biologics.

The COVID-19 pandemic is getting worse. According to the World Health Organization (WHO), as of Thursday morning, there were more than 125,000 confirmed cases in the world, and the novel coronavirus had caused more than 4,600 deaths.  The importance of developing vaccines and treatments for this rapidly spreading disease can hardly be overstated.  

In light of that, a host of drugmakers are already looking to find ways to treat or prevent COVID-19, and the latest to join their ranks is  Eli Lilly (LLY 0.27%), the world's tenth-largest pharmaceutical company. On Friday, Eli Lilly announced it had entered into a partnership with a privately held AbCellera Biologics, which focuses on developing therapeutic antibodies. 

Test tube filled with blood for Coronavirus testing.

Image Source: Getty Images.

A race to beat COVID-19

Eli Lilly will bring its capacity for "rapid development, manufacturing and distribution of therapeutic antibodies" to this partnership, while AbCellera will make use of its "rapid pandemic response platform." It's worth mentioning that after receiving a blood sample from the first U.S. patient who recovered from COVID-19, AbCellera was able to identify 500 antibody sequences with the potential to be effective against SARS-CoV-2 (the virus that causes COVID-19). That's the largest known pool of potential antibodies against the novel coronavirus. 

The company will now try to identify which of these 500 antibodies could be the most effective against SARS-CoV-2. While it will be worthwhile to keep an eye on this partnership between Eli Lilly and AbCellera -- and how their joint efforts progress -- other pharmaceutical companies are further ahead in their quests to beat COVID-19. On Feb. 26, Gilead Sciences (GILD 0.83%) announced the initiation of two phase 3 studies to investigate the efficacy of its antiviral drug remdesivir as a potential treatment for COVID-19. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.32 (0.83%) $0.51
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$325.10 (0.27%) $0.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.